Latest / Newcomer Pod / Life Extension Innovations, Moonshots & Snake Oil (with Celine Halioua & James Peyer)
Transcript
- 0:01Hey, it's Eric Newcomer. Welcome to the Newcomer podcast,
- 0:04Probably my favorite episode ever.
- 0:06This week a conversation with James Pyer, the CEO of Cambrian
- 0:11Bio, and Celine Haliwa, the CEO of Loyal.
- 0:16James is trying to help humans live forever, and Celine is
- 0:20trying to help your dog live as long as possible.
- 0:23We get into life extension and longevity, Silicon Valley's
- 0:28chase to fight off death. You've probably read about tech
- 0:32mogul Brian Johnson. He was just profiled in time,
- 0:36who's desperately trying to figure out ways to optimize his
- 0:38life to drag it out as long as possible.
- 0:42Celine and James are skeptical of that effort.
- 0:45Spoilers. We get into what's credible, the
- 0:49moon shots and the snake oil in the life extension and longevity
- 0:53space. If you're curious about Silicon
- 0:56Valley's effort to live forever, you want to fend off death.
- 1:00This is a great dive and with sort of serious players in this
- 1:05space about the effort to find drugs that will keep people and
- 1:12our pets living longer. Give it a listen.
- 1:15Celine and James, thank you for joining the podcast.
- 1:18Welcome. Nice being here, Eric.
- 1:20Yeah. Thanks for having us life
- 1:22extension longevity, like things everybody wants for themselves
- 1:26and to know how they can live longer and it's a fun space to
- 1:30talk about. So really, really excited for
- 1:34this episode. I mean, I I think just start
- 1:37off, can you each give the sort of 1st 30 seconds how you came
- 1:43to the longevity space? Next 30 seconds, just like at
- 1:46the high level, we'll dig into it more like what your company
- 1:49does, so people know who we're talking to.
- 1:51Celine, do you wanna start us off?
- 1:53Yeah, so I got interested in aging and longevity kind of
- 1:58indirectly. I was working, so my undergrad's
- 2:00in neuroscience and I have an incomplete PhD in health
- 2:04economics. And while I was doing research
- 2:06in Neuro, we were working in a Parkinson's lab.
- 2:09And Parkinson's, A neuro time disorder that is predominantly
- 2:13caused by a loss of a certain type of neuron, that is.
- 2:16Infamously difficult to treat with modern therapies.
- 2:19And I remember sitting in this lab thinking, why are we waiting
- 2:23until there's decades of damage and decades of neuronal loss?
- 2:26So start trying to treat the patient instead of trying to
- 2:28understand what led to them having this loss of brain
- 2:33function. And so that kind of Long story
- 2:35short, led me into the aging field, which the way I think
- 2:37about aging drugs is preventative medicines for
- 2:39multiple age-related diseases at the same time.
- 2:42So not nearly as sexy as. Of 20 year lifespans,
- 2:45immortality, saving Johnson's Johnson, things like that.
- 2:49Sorry, I had to. We'll get into him.
- 2:52We'll get into him. We'll get into that I'm sure.
- 2:54And now I run a company called Loyal.
- 2:58We're developing what we hope to be the first FDA approved drugs
- 3:02explicitly designed to extend the lifespan and health span.
- 3:06And we're specifically working on dogs, dogs.
- 3:09So yeah, that's, yeah, that's the take away.
- 3:12You're starting with dog. It's easier, we'll get into it,
- 3:15but it's easier to extend the lifespan of dogs than humans
- 3:18because of regulation, right. I mean, it's sort of regulatory.
- 3:22It's honestly just a like a logistics thing or anything
- 3:24else, right? Like a dog.
- 3:26Well, like one of the core ideas is that big dogs live very short
- 3:29lives. You know, a great day might live
- 3:30678 years while Chihuahua lives 18 years.
- 3:33You can see aging and you can see lifespan in a dog in a much
- 3:36shorter period of time than you can or a person.
- 3:38If I give you guys a lifespan extension drug, I'm not gonna
- 3:41know if it works or not for a really long time.
- 3:43Good luck like getting some VC to fund that, not the less the
- 3:46clinical studies. My wife's family has a black lab
- 3:49named Moon Unit that I've gotten very attached to and.
- 3:52Well, we're working on it. Yeah, exactly.
- 3:54Chop, chop. The realization that I, you
- 3:56know, you're getting attached to a big dog halfway through their
- 4:00life is sort of like, Oh no, what am I doing like?
- 4:03Anyway, I have a senior Roddy who I'm in love with.
- 4:06And yeah, yeah. So anyhow, that's what I'm up
- 4:09to. All right, James, what about
- 4:11you? How did you get into this space?
- 4:13So my story starts in the late 90s when.
- 4:18The the aging space was really act like academically in its
- 4:22infancy in a lot of ways. And we had just kind of
- 4:25discovered that there were these things inside of each of our
- 4:28cells called telomeres that shortened every time a cell
- 4:32divided. And a couple of books got
- 4:34published in the late 90s when I was a student that said, hey, if
- 4:38we can extend, like prevent the telomeres from shortening and
- 4:41keep them long, then cells should be able to live forever.
- 4:45And then sure enough, like right after that, we were able to take
- 4:48normal human cells and let them divide an infinite number of
- 4:50times by keeping their telomeres long.
- 4:52And then that led to this explosion of, Oh my God, is this
- 4:55the answer for aging. And it turned out not to be the
- 4:58case, but it kind of sent me down this path.
- 5:01Similar to Celine's story of like, this could be the core.
- 5:06Not telomeres specifically, but like the study of why our cells
- 5:09and our organs stop working as we get it.
- 5:12Old that could be the key to keeping people healthy, the key
- 5:15to preventing diseases from from happening in the 1st place.
- 5:20Around the same time, my grandfather was diagnosed with
- 5:23cancer, which kind of went from zero to 60.
- 5:27And he was, you know, treated, failed treatment and was gone
- 5:33within a year and a half of his diagnosis.
- 5:36And I just saw how to Celine's point about Parkinson's.
- 5:38Like how? Futile.
- 5:41It was to wait for decades of molecular damage, right?
- 5:47Decades of a disease to build up bit by bit.
- 5:49Cancer I think, is a great example of this where it has to
- 5:52go through one mutation, big expansion bottleneck, expansion
- 5:56bottleneck before ever even thinking about how do we treat
- 5:59this, how do we stop this from happening.
- 6:02And for the past 20 years I've been either as a researcher or
- 6:06for the last almost 10 as a kind of.
- 6:10Investor, company, builder and now executive in this space have
- 6:13been trying to ask the question how do we take these discoveries
- 6:17from the academic world and understanding how our bodies age
- 6:21and turn those into medicines with the thesis that's almost
- 6:25100% aligned with with Celine that like this is not about.
- 6:30You know, longevity or even health span.
- 6:32That the the best and highest use of these breakthroughs in
- 6:35our understanding is to create a new generation of preventative
- 6:39medicines. That if you Fast forward 50
- 6:41years, people are going to look at this research now and kind of
- 6:44equate it with what happened in the first half of the 20th
- 6:47century with vaccines and antibiotics.
- 6:50These were the biggest killers of humanity.
- 6:53And now we've figured out ways of understanding how they work
- 6:56and how to get there before the disease like robs us of our
- 7:00ability to to deal with them by becoming so complex and so, so
- 7:04damaging. Cambrian is is kind of a unique
- 7:07company that I run. So, so we partner with academics
- 7:10who have made breakthroughs in aging research all over the
- 7:12world, who have figured out ways to create a drug that can target
- 7:17a different aspect of aging. And then we bring that into
- 7:20Cambrian and move that forward into human clinical trials.
- 7:24So we don't have any dog FDA stuff pending.
- 7:27Our strategy is slightly different which is we find a
- 7:30drug that has the potential to slow these aging processes to
- 7:34prevent disease, to extend health span.
- 7:36But we say, all right, well, this could be a great cancer
- 7:39drug. It could be a great.
- 7:40Drug for heart disease. It could be a great drug even
- 7:43for like a rare orphan genetic disease.
- 7:45So let's start there and after we show safety and efficacy,
- 7:49then you can do something closer and closer to prevention.
- 7:52The idea is you're picking drugs that you think would sort of be
- 7:56useful to the general person or that have some reason why they
- 7:59would be preventative. That's right.
- 8:02And so we can get into some aspects of this, but it looks
- 8:04actually like we're going to be able to start our first
- 8:06preventative trial in human patients as early as the end of
- 8:10next year. So you guys are both sort of
- 8:13hinted at this, but just defining the space longevity,
- 8:16life extension from what you're saying like there's a sort of
- 8:19innocuous way to phrase it, which is just sort of
- 8:20preventative medicine, right? Or am I wrong?
- 8:24Is saying that like a core idea here is that most drugs are
- 8:28meant to treat people where something's like clearly wrong
- 8:32and there are somewhere outside of the human baseline.
- 8:35And a key idea here is that even if you're at the human baseline
- 8:39or over performing, are there drugs we should give you earlier
- 8:43in your life that that give you a better outcome?
- 8:46Is that the right way to think about it?
- 8:48Would you quibble with anything or add anything there?
- 8:51What I've found has been kind of the aha moment when I'm trying
- 8:55to It's a lot of my job fundraising and also activating
- 8:58and educating pet parents and vets is explaining what is this
- 9:02aging thesis. And the way I think about it is
- 9:05that as we get chronologically older, the cells that make up
- 9:12our body accumulate damage. They, you know, accumulate
- 9:16mistakes, etc. And these are inherently things
- 9:20that occur overtime. And a disease that's associated
- 9:23with this damage or decaying or loss of resiliency, a loss of
- 9:27function, depends on where it's happening, right.
- 9:29So if it's happening in your brain, it might lead to our
- 9:31dementia or an urgent disorder. If it's happening in your joint,
- 9:34it might lead to osteoarthritis, it's happening in your immune
- 9:36system, it might lead to cancer. And these things are classically
- 9:39thought of as completely unrelated diseases, right?
- 9:42Having osteoarthritis considered mechanistically very different
- 9:45from having Parkinson's and at the end stage.
- 9:48They are. They are very mechanistically
- 9:49different. An OA drug isn't going to most
- 9:52likely positively impact dementia, but the underlying
- 9:55drivers that led to a patient developing diseases, the
- 9:59processes of aging, the processes of damage are
- 10:02conserved or that's a piece of the field.
- 10:04So if you develop a drug that targets the way a body breaks
- 10:07down over time, it may have a positive impact on these
- 10:10classical diseases that are today thought of as totally
- 10:13separate and one like nice. You know anecdote to that is the
- 10:17only lifespan extension study has been run to completion in
- 10:20dogs. Was actually run by the dog food
- 10:22company Purina in the late 1990s.
- 10:24There was a cleric restriction study which is kind of the OG
- 10:27way to extend lifespan is one of the reasons why tech grows
- 10:30intermittent fast and they showed a tier lifespan extension
- 10:33in Labradors. But more interestingly to this
- 10:36thesis they showed A2 year delay in incidence of cancer and
- 10:40osteoarthritis. Again, two single.
- 10:42If they do what? Sorry, what's the?
- 10:44Caloric restriction. So these two unrelated diseases,
- 10:49cancer and osteoarthritis. There was a delayed incidence of
- 10:52almost two years in these dogs who are calorically restricted
- 10:56compared to the dogs that weren't.
- 10:59And so that suggests that these dogs are potentially aging at a
- 11:02slower rate or aging more healthily, which is why they
- 11:05lived longer, but also why these unrelated age-related diseases
- 11:08developed later. In life.
- 11:09So that's how I think about it. And we can do this
- 11:11pharmacologically as well. So like Celine said, like the OG
- 11:15way of extending lifespan in animals was to just reduce their
- 11:20number of calories. And like you go into this, your
- 11:22body goes into this like famine preservation sort of mode.
- 11:26Some processes run slower, but overall your lifespan is
- 11:30extended and there's now more than 80 different.
- 11:35Drugs or genes that you can tweak that not in dogs, which
- 11:38are bigger and more complex and live longer.
- 11:40My background is as a mouse geneticist, so so you know, I I
- 11:43live in the world of mice more than dogs.
- 11:45But in mice, you know their natural lifespan is only about 2
- 11:481/2 years. So you can run these studies in
- 11:51mice really, really easily and with large numbers to get good
- 11:54statistical confidence. And a drug like there's one
- 11:57called rapamycin that a lot of people know about and talk about
- 12:01which hits this this pathway called M Tor.
- 12:04M Tor is one of the key pathways that is on when we're eating
- 12:07three meals a day and gets kind of cranked down when we are not
- 12:12eating three meals a day, right. When you eat once a day or you
- 12:14know if you're reducing your number of calories and just by
- 12:18giving small amounts of this drug to mice, you can increase
- 12:22healthy lifespan by like close to 20%.
- 12:25And you get exactly that same phenotype that Celine is talking
- 12:27about where it's that the reason that the mice are living longer
- 12:30and healthier is because they're.
- 12:33Memory is working better, they get less cancer, their skin is
- 12:36in better condition, their joints are in better condition.
- 12:38And it's all of these things happening at once, because
- 12:40you're fiddling with something core to how cells and tissues
- 12:45function properly, not waiting for, like trying to untangle
- 12:49that this very, you know, disease specific, what's the
- 12:51name of that drug? It's called rapamycin.
- 12:54Are people taking that? So this is.
- 12:56A triggered. This is a whole, so rapamycin is
- 13:00actually an FDA approved drug. And the things that it is FDA
- 13:04approved for are and it's sort of like it's got a couple of
- 13:08variants, but it was first approved as an immunosuppressive
- 13:12therapy for people who are getting kidney transplants
- 13:14because large amounts of this drug actually suppress your
- 13:17immune system. And then it was kind of approved
- 13:20for two other things which is treating sort of mid to late
- 13:23stage cancer patients to prevent their tumors from growing.
- 13:26And then finally there's a specific rare disease that where
- 13:30this this pathway is cranked up that causes epilepsy and giving
- 13:34this can reduce the number of seizures.
- 13:36So those all three are like high doses of this and it's never
- 13:41been widely experimented in low doses in humans.
- 13:44Some people are self medicating but.
- 13:48Man, we just don't know very much.
- 13:50And the difference between the low dose and a high dose and
- 13:53like when you jump into potential side effects versus
- 13:55when your dose is too low and there's just going to be no
- 13:58benefits. We have no idea in America am I
- 14:03allowed as an individual to take a drug off label of my own
- 14:07direction, or what sort of the freedom an individual has to
- 14:11take a drug that's prescribed for one thing and mess around
- 14:14with it for other reasons. So there's two levels here.
- 14:18There's first what your doctor can do.
- 14:20So a physician in the United States is allowed to prescribe a
- 14:26drug off label with no restrictions.
- 14:29If if your doc said hey Eric, like take this drug, it's for
- 14:33breast cancer, but you know you have whatever and I want you to
- 14:37take this. Like there is no authority that
- 14:40can stop the doctor or you from making that decision.
- 14:44There are two sort of like upstream ways that that happens
- 14:48less. First is that your insurance
- 14:50company may not pay for that drug and there are prohibitions
- 14:55from, let's say I run the biotech company that created
- 14:58that drug for breast cancer. I can never tell the doctor, oh
- 15:01please. Also you know recommend it for,
- 15:05I don't know cough or something like this, right?
- 15:08So upstream, those are the protections we have in place.
- 15:11But the doctor patient relationship is pretty open,
- 15:16Yeah. Do you consider like Ozempic
- 15:21wigovy to be life extension drugs you want?
- 15:25To stop, You're the human guy. OK.
- 15:29I can say intent put. Put that on my tombstone, the
- 15:33human guy. I'll say this, my favorite
- 15:38little anecdote about weight appetent suppressants is that
- 15:42one of the bigger dog drug failures was a drug that was a
- 15:46weight loss drug for dogs as approved years ago that worked
- 15:50predominantly by suppressing the desire to eat and it was a huge
- 15:53market failure despite the fact that dogs have a very high
- 15:56incidence of obesity, just like humans.
- 15:58The reason being is that people they perceive their dog wanting
- 16:02dinner or wanting a treat as love.
- 16:05And so when the dog suddenly isn't hounding you for dinner,
- 16:08isn't hounding for a tree, and it's just kind of ignoring you,
- 16:10they're like, God, my dog doesn't love me as much.
- 16:12Like, oh, cheated. So one of the things we
- 16:14explicitly look at in our studies is ensuring it doesn't
- 16:18reduce desire to eat and doesn't reduce weight.
- 16:22Because it would probably be a commercial failure, so I will
- 16:24not be doing Ozempic for dogs. But James, I'm sure you have
- 16:28more human biology expertise here.
- 16:31So what I would say on the more critical side, jumping off from
- 16:34what Celine was saying, is that Ozempic is not a drug that I
- 16:38think is suitable for everybody, right?
- 16:41We're not going to end up in a situation where really healthy
- 16:45people who have a great diet and exercise are in relatively good
- 16:48shape, but aging should go on Ozempic, right?
- 16:51But it is a. Really damn good drug for
- 16:53obesity, and it looks like the effects are just really powerful
- 16:58for obesity and for type 2 diabetes.
- 17:00Like this is worthy of its blockbuster status.
- 17:04The main drawback that makes this from a risk reward
- 17:08perspective, good for diabetics and people who are obese, but
- 17:13not good for people who don't have those things.
- 17:16Is that when you stop eating? Because that's the way that this
- 17:19drug works, right? You.
- 17:20You feel full even if you haven't eaten that much.
- 17:23When you're not eating, you consume more fat for calories,
- 17:26but you also consume muscle. So even for these people that
- 17:29have a lot of extra fat, about 1/3 of the weight that they lose
- 17:33is actually muscle mass. And if you look in people who
- 17:36are older, right? So in your 20s and 30s, if you
- 17:39lose a little bit of muscle mass while you're.
- 17:42Cutting off a lot of extra adipose tissue, you can then hit
- 17:45the gym and rebuild that muscle mass.
- 17:47But like, once a person is about 60 or so, like, rebuilding that
- 17:52lost muscle is really hard and it increases your risk of all
- 17:57sorts of other things, right? It basically makes people more
- 17:59frail, so they're more likely to fall, more likely to get
- 18:02orthopedic or sports type injuries if they lose a bunch of
- 18:05muscle. And so talking our own book
- 18:08here, a little bit similar to what Celine's talking about in
- 18:10her dogs, The drug that Cambrian has that is furthest along, it's
- 18:14actually already treating human patients is a drug that also
- 18:19targets. It's kind of like the flip side
- 18:20of the Ozempic GLP, one coin where Ozempic makes you eat
- 18:25less. But what if, instead, your body
- 18:27thought it was exercising more? And so the same kind of group of
- 18:30people that have been studying aging biology have known that
- 18:33exercise is one of the best things we can do for aging since
- 18:36forever. And the main way that our body
- 18:38gets the positive benefits of exercise translated into
- 18:42increased muscle mass and more calorie consumption is by
- 18:44activating A pathway called AMPK.
- 18:47And Cambrian has the first drug that activates AMPK safely that
- 18:53has already started human trials.
- 18:55And what we see is just like. In in obesity studies, you see
- 18:58the same sort of thing where like you can put mice on a high
- 19:00fat diet and they lose weight even if they're eating more than
- 19:06than mice off the drug. How much?
- 19:07That's more in that trial. So it's been in about 100 people
- 19:11so far. And then the study that we're
- 19:13doing will have about another 50 people treated over the next
- 19:15year. And do you own that drug
- 19:17outright or is it sort of a minority stake or how does that
- 19:20actually work? So the way that Cambrian works
- 19:23is we own a majority stake in every drug in our pipeline
- 19:28underneath us, but we don't own 100%.
- 19:31We kind of share that upside, usually with specific scientists
- 19:35that have. Kind of been working on those,
- 19:38those products, sometimes other investors as well that have been
- 19:41working on these products since before we got involved.
- 19:44So we're not like a private equity group that's coming in
- 19:47and acquiring things. We're coming in and we're taking
- 19:50a controlling stake, but leaving upside for other people that
- 19:53aren't want to ride this train along with us.
- 19:56It's a cool business model. While we're talking around
- 19:58books, yeah, what's the drug that you have this farthest
- 20:00along? For dogs.
- 20:02Yeah. So one thing I wanted to quickly
- 20:03note and then I'll answer your question is what James is saying
- 20:06about safety is super key. It's like actually one of our
- 20:09key philosophies when I started the company is the drug might
- 20:12not work, but it shouldn't do any harm.
- 20:14The way to think about the safety of an aging drug is, and
- 20:17I believe there's a quote from an ex FDA individual is that it
- 20:21needs to be basically as safe as water.
- 20:23And the reason being is because if I'm giving you a drug today
- 20:26to prevent something you may or may not get in the future and it
- 20:28kills you tomorrow or maims you tomorrow.
- 20:31That risk reward, it's not acceptable.
- 20:33Or even having increased risk of something bad happening to you
- 20:36like increased frailty is not acceptable.
- 20:39So that's one of the challenges of the field and one of the
- 20:41reasons like James and I are working on relatively simple
- 20:44drugs, so to speak. There's a lot of companies that
- 20:46are doing these like really sexy, you know, epigenetic
- 20:49reprogramming, gene therapy, da, da, da.
- 20:51And like my work might not work. We'll see.
- 20:53But at least I can't speak for James.
- 20:55I'm pretty sure you're mostly doing boring molecules.
- 20:57I'm only doing boring molecules. And that's because safety is so
- 21:02important and you just don't want to introduce variables when
- 21:05you don't know how something will behave in the body.
- 21:08I think that's also been key and this is an interpretation.
- 21:11They haven't hit this to me explicitly, but I think that's
- 21:13been key to a lot of our success with the regulatory bodies is
- 21:17demonstrating safety far and beyond what is required of us
- 21:22legally. To answer your question on talk
- 21:25in our talk in our book, I was trying to think.
- 21:27Have like a metaphor. Like a dog.
- 21:29Our furthest along drug is a daily drug for old dog lifespan
- 21:33extension. So for dogs of almost any size,
- 21:36any breed, for already showing signs of aging and you know, if
- 21:40everything goes well, we're running towards it being on the
- 21:43market in 2025. Really 2025.
- 21:46So lots of work. I know, I know.
- 21:48It's so cool. Lots of work.
- 21:50You you've passed some trial or is it the same with dogs we have
- 21:54trials or? Yeah.
- 21:57So we've completed the safety studies awaiting FDA feedback,
- 22:00but it looked really nice. We've completed the efficacy
- 22:04work, awaiting feedback from the FDA.
- 22:06And then the thing that kind of determines our go to market
- 22:08timeline is actually manufacturing.
- 22:11And manufacturing is like a pain in the ass.
- 22:12It's hard, don't get me wrong, but it's a great problem to have
- 22:17because it's completely physically possible to
- 22:19manufacture a beef flavored pill at scale.
- 22:22It's really just like how operationally competent are we
- 22:24ever gonna pick the right supply chain partners, We're gonna
- 22:27manage them correctly or we're gonna see around corners.
- 22:29So you know if we're wrong and like we're quarter delayed or
- 22:32something. It's not a binary existential
- 22:34thing. Assuming the FDA agrees was the
- 22:36technical packages that we believe are very strong showing
- 22:39that the drug does what we think it does, what's the mechanism
- 22:43for this drug? Yeah.
- 22:44So kind of what James was talking about earlier with
- 22:46caloric restriction when we started the company, we wanted
- 22:49to take his little biological risk.
- 22:51As possible, right? Like it is almost certainly true
- 22:53that you can extend a dog's lifespan with a drug because
- 22:56we've done it and everything from you know yeast to mice all
- 22:59the way up and there's correlation data and people.
- 23:01So it'd be weird if that wasn't possible also in dogs.
- 23:05The question then what is the highest probability and also
- 23:07safest thing that we could use in dogs to show that a drug can
- 23:10be approved for lifespan extension.
- 23:12And so as I mentioned earlier, the only lifespan extension
- 23:15study that I'm aware of that's been run to completion and dogs
- 23:17is at Purina lifespan extension study, which is using chlor
- 23:20restriction. And so the drug emulates the
- 23:23benefit or the molecular impact that has had on the dogs when
- 23:27they chlorically restrict specifically working on
- 23:30metabolic fitness and also fat tissue function and the
- 23:33age-related decline of fat tissue function.
- 23:37Cool. I mean we've sort of touched on
- 23:39sort of different parts of life extension you both have invested
- 23:43also and sort of see the space just sort of like a framework of
- 23:46sort of the different categories of longevity that we're sort of
- 23:51seen from what you're saying you're like okay, we're like
- 23:54simple molecule to sort of the most like far out there which
- 23:58you said like epigenetic or just give me this sort of roadmap of
- 24:02the different buckets of this that are happening right now.
- 24:06I can take a shot at that one. Yeah, I know that's like the
- 24:09bucketing the world. That's like frameworks.
- 24:11Yeah, yeah. And he's the real investor.
- 24:13I just late investor. I did, I was at Longevity Fund
- 24:17and I like invest a little bit personally, but I'm a much
- 24:20better founder than I am investor.
- 24:22So the way that I look at this space, I'm gonna give a title to
- 24:28three different buckets. I'm gonna call them innovations,
- 24:32Moon Shots, and Snake Oil. And I think spicy.
- 24:37I love it. Come with the spice, James.
- 24:39Like innovations, Moon shot? Reading on this podcast and
- 24:42snake oil. Yeah, hell yeah.
- 24:44Who's gonna be in the snake hole, loyal?
- 24:47So, so I would describe innovations as anything that
- 24:53looks an awful lot like other preventative medicines that we
- 24:58can like draw a Direct Line from that work to us.
- 25:02Right. And there's a series of
- 25:04preventative medicines that I think are really going to be
- 25:06useful comparators to the first true drugs that we think of as
- 25:11coming out of the longevity or aging biology space that like
- 25:13everyone's going to draw comparisons to like statins,
- 25:16right. So we already talked about
- 25:17Ozempic, which I think is going to have a lot of comparators
- 25:20because a lot of these drugs are going to come in for cardio
- 25:22metabolic disease. Statins is the other fantastic
- 25:24example where like you have a risk factor and you.
- 25:28They start giving people a drug based on their risk factor to
- 25:31prevent heart attacks and strokes and so.
- 25:33So I think those parallels which like Selena already touched
- 25:36upon, they are every single one of them small molecules that
- 25:41have a really good safety profile that target well
- 25:45understood molecular mechanisms mostly having to do with
- 25:49treating metabolic health. There's this big mess of cardio
- 25:53metabolic, like how our heart works and how our our metabolism
- 25:56work. That's sort of where the first
- 25:59wave of innovation, I call it the first dominoes to fall, are
- 26:03going to be in that innovation bucket.
- 26:05My second bucket is moonshots, which is like we have some
- 26:09really powerful, interesting ideas, many of which are getting
- 26:13funded, that are sort of like a next layer of where this space
- 26:18could go. And things like, you know,
- 26:20probably the interface between innovations and moonshots is
- 26:23like biologics that we have. For example, there's a protein
- 26:26that's naturally produced in people that when it's present
- 26:31prevents a woman from going into folliculogenesis, prevents
- 26:36someone from ovulating so. So with an injection of this
- 26:39protein, one could potentially completely control ovulation,
- 26:43which we think if you then maintain the ovarian reserve,
- 26:47could prevent menopause. Like, that's a cool ass idea,
- 26:51right? It's more complicated than a
- 26:53small molecule daily pill that's affecting metabolic disease.
- 26:57But like, that's the kind of cool moon shot type approach
- 27:02that one of the ones that we're taking.
- 27:04There's also stuff like reprogramming.
- 27:07The epigenetics of a cell is one that's talked about a lot to
- 27:10like a more immature state. So that then it can become kind
- 27:13of repair damaged tissues. It's another moon shot that has
- 27:16like some really promising data coming out.
- 27:19Especially there's a company called Life Biosciences that has
- 27:22reversed like eye diseases or optic nerve damage in monkeys
- 27:27already and like so that will be probably used for more specific
- 27:32functions, right? Like in the.
- 27:35Menopause case, it'll probably be used in IVF first.
- 27:38The epigenetic reprogramming will probably come out in like
- 27:41nerve degeneration in the eye 1st.
- 27:43And then if it's safe, if it's really, really safe, then it can
- 27:48expand, especially if it can walk in the sort of footprints
- 27:53in the snow made by the innovative drugs, right.
- 27:56And one of the reasons I'm so excited about the work that
- 27:58Selena's doing is because of the strategy that she's taken in
- 28:01Dogs Like She's. Jumped ahead of the rest of us,
- 28:06you know just human people in terms of talking about this
- 28:09multi disease prevention, correcting metabolic dysfunction
- 28:13to prolong health span and like hopefully that will allow us to
- 28:18walk in loyal's footsteps a little bit as we talk about
- 28:20doing this in people. Yeah, you guys are welcome.
- 28:24I think it should take a tax on all the longevity companies.
- 28:27Like you guys need to give me like 5% of your fund.
- 28:32Especially the epigenetic companies that raise like a
- 28:34billion dollars. I mean, and to be honest, I
- 28:37wanna say like this, this moon shot category, I don't wanna
- 28:41throw any shade at that because I think that those techniques
- 28:45and technology and the biology underlying a lot of this is
- 28:48really damn exciting. It's.
- 28:51Throw some shade, I can throw your well, yeah, we're all
- 28:54waiting for the snake oil category.
- 28:56Come on. Okay.
- 28:57And then the third. 1 can be thrown here too though.
- 28:59Right. The third one for me is then the
- 29:01snake oil category, which is basically everybody who is
- 29:05taking advantage of the fact that longevity has become one of
- 29:08the biggest, let's call it mega trends of like fascinations of
- 29:12people, especially in the developed world over the last
- 29:15three or four years. And realize that even without
- 29:20validating any new technologies, we can just like sell stuff to
- 29:24people who are scared of their own mortality and scared of
- 29:27their own decline the way that humans are.
- 29:30If you're super rich post post wealth, what do you wanna spend
- 29:33your money on Like living longer?
- 29:35Higher quality of life? And especially if you control a
- 29:38venture fund, not even your money.
- 29:40What do you wanna throw it at? Things that could.
- 29:42Yeah, it's interesting, I think that.
- 29:46Where the bigger bucket of snake oily things are living is
- 29:50outside of the venture backed company space.
- 29:52It's more in the direct to consumer space stuff that's like
- 29:55we want to sell stuff to people. Now what can we sell?
- 29:57What can we make profit on today?
- 29:59That's the biggest snake oil bucket.
- 30:01We're like the red flag that jumps in my mind is like, OK, is
- 30:05your R&D and clinical trials, is that coming out of an actual R&D
- 30:09budget or is it coming out of your marketing budget so that
- 30:11you can run ads on Facebook and Instagram saying?
- 30:15Clinical trials suggest this. And if it's the latter category,
- 30:18it's probably in the snake oil bucket.
- 30:20I think there's been a bunch of efforts over the past three or
- 30:25four years to try to establish some kind of standard around
- 30:28what good looks like and it all kind of funnels down to are you
- 30:33going to run clinical trials to test whether this thing actually
- 30:39works before you start selling it?
- 30:41And if the answer is yes, you're probably in bucket one or two.
- 30:44If you're serious and the answer is no, or you say you are, but
- 30:48you've really got no shot at it and there's no real plan there,
- 30:51you're probably in bucket 3. The snake oil companies are, you
- 30:55know, you could argue that they're like trying to get
- 30:57things to consumers immediately. Drugs take years to get approved
- 31:00da da da da. But I think that they don't
- 31:02realize, like the biggest hurdle I have to overcome when I'm
- 31:04educating veterinarians and regulators, what we're doing is
- 31:07that it's legit, right? Like the number one pushback we
- 31:11get is It sounds too good to be true or.
- 31:14Is this, is this really real? Is this just like, you know
- 31:16fountain of youth stuff And that's dangerous.
- 31:19It's dangerous for a field because it means legitimate,
- 31:21skeptical people are not going to engage in it or much more
- 31:24difficult to engage in it. So all the kind of, you know,
- 31:28we're here to make thousand year lifespans, even 120 year
- 31:31lifespans. Like, maybe it's possible, but
- 31:33leading with that is was so unnecessarily controversial was
- 31:36often just an attempt to get, you know, earned media so more
- 31:39people will buy their thing versus leading with, you know?
- 31:44Good science and that these are preventative medicines to reduce
- 31:46risk of future disease, which is the most consensus thing on the
- 31:49planet, right? To reduce the risk of developing
- 31:52a future disease cheaply and safely.
- 31:54So yeah, these people piss me off.
- 31:56What are people shit every day? You know this?
- 31:59I mean, it's like they're sort of like vitamin type pitches or
- 32:02what? Vitamins are common, yeah.
- 32:06So I think there's also a bunch of like.
- 32:09Interventional stuff that can be done without regulation.
- 32:12So there's a big push in stuff that.
- 32:15And like, the big tragedy for me is some of these things may
- 32:17actually be helpful. We just don't know because no
- 32:19one's really like the worst. People are so busy selling this
- 32:23that no one's really asking the scientific questions, right.
- 32:25So there's like people out there, you know, offering 10s of
- 32:30$1000 for your daily hyperbaric oxygen containment and like.
- 32:36You know, you got to do these ice baths and you got to do
- 32:38these skin treatments and you got to do this, you know,
- 32:42plastic transfusion. Yeah, OK.
- 32:44That like. Like those things do exist.
- 32:46Blood transfusion in the room. Like do you where is that fit in
- 32:51in this because I mean blood boys, I feel like that's what
- 32:54sort of the regular persons taken from Silicon Valley or the
- 32:57show or whatever, you know? So I think it's a perfect like
- 33:00microcosm of. Both the scientific potential
- 33:04and the hucksterism and snake oil possibilities of this.
- 33:08Cuz like if you go down to what got people excited, there are
- 33:11some mouse experiments where you took young plasma, put it into
- 33:15an old mouse, and the old mouse just got better in a lot of
- 33:19ways, right? And you take the old plasma, put
- 33:21it into the young mouse, the young mouse behaves worse.
- 33:24Figuring out why exactly has been.
- 33:28Actually kind of a fraught scientific odyssey where we
- 33:30still don't have good answers as to why after almost 15 years of
- 33:34looking at it. And there have been some
- 33:37companies. The one that I'm most admiring
- 33:40of is called Alkahest, which spun out of Tony Whiskerrey's
- 33:43lab at Stanford and actually created what they called drugs
- 33:47based on chrono kinds. So things that either go up as
- 33:52you age and therefore you want to remove, or go down as you age
- 33:55and therefore you want to replace.
- 33:56And they were able to use this to say like, oh, well, these
- 33:58could be good drug targets. And they were actually bought by
- 34:02the biggest plasma company in the world called Grifols, which
- 34:06is a Spanish pharma company. And they were as like a positive
- 34:09story both from a pharma perspective and from a venture
- 34:13kind of like investment perspective.
- 34:15So like, that's a nice little story that I can get behind and
- 34:18I have a lot of respect for the people of Alca Hest doing
- 34:20something hard and pioneering and then on the other side you
- 34:23have like. Whether it's people trying to
- 34:25open individual clinics or or physicians or non physicians who
- 34:30are like OOH, I'll bet we can sell plasma for whatever $4000 a
- 34:36pint to people who heard about these mouse experiments and for
- 34:40whom we have really no evidence that this will help them.
- 34:42But you know, there was a piece in the Guardian or whatever
- 34:46saying that it worked parentheses in mice.
- 34:50And like that's that snake oil bucket.
- 34:52And like I would say 98% of the conversation that we hear in the
- 34:56media or out in the lay press is about that second bucket and 10%
- 35:01is about the actual science that has been making some positive
- 35:05steps. And there's a couple of other
- 35:06companies that are trying quietly to do some hard but
- 35:09interesting work in that space. We're not one of them.
- 35:12But I have a ton of respect for those people and I think that
- 35:15the core scientific insight, like there's probably something
- 35:17there that could be important. We just don't know exactly what
- 35:20it is. Yeah.
- 35:21All right. I feel like this is the time to
- 35:23bring up Brian Johnson, which I have generously not led this
- 35:26conversation with. But, you know, he's the rich guy
- 35:30who's, you know, doing a bazillion different things to
- 35:33extend his life, recaptures youth.
- 35:35The media is, like, fascinated by it, you know.
- 35:39Yeah. As serious people in the space,
- 35:41what do you make of what he's trying to do?
- 35:46My short answer is I think the best thing Brian Johnson could
- 35:49do to extend his lifespan would be investing in loyal or
- 35:53Cambrian or another legitimate aging company.
- 35:57Does it have to be us? I understand the grift, but I
- 36:02think he doesn't understand pharma and drugs and the reality
- 36:07of actually getting something approved.
- 36:09I don't think he's ever going to work getting something approved
- 36:12or statistics, you know, science.
- 36:14Physics, you know, all these things, which is fine.
- 36:18You don't have to. I mean, I I can't code right,
- 36:21but it actually slows down the progress of the field.
- 36:26Like the biggest issue I have to worry about when I'm fundraising
- 36:31is making sure people don't feel like we're the next serrano's or
- 36:34like other illegitimate thing that's going to embarrass them.
- 36:36Embarrassment insurance. Trump Insurance is a huge thing
- 36:39that I have to build into everything I do when I'm
- 36:42fundraising for this company. And I'm a really fucking good
- 36:45fundraiser, right? So think about like, how many
- 36:47people who have, like, interesting scientific concepts,
- 36:50new drugs that should get piloted.
- 36:51I just aren't happening because there's such a negative bias
- 36:54when you're coming in with this field.
- 36:56It's not just because of him. But he sure as hell isn't
- 36:58helping, and I wish you'd use his platform to educate in a way
- 37:04that would promote the entire field and not become a problem
- 37:06that I I literally have to explain away probably once or
- 37:10twice a week. Are there things that he's doing
- 37:14that make sense or don't, or I don't actually know all the
- 37:16different? Do you have a sense of what he's
- 37:18actually doing? People are constantly
- 37:21experimenting with their own sort of personal fitness to try
- 37:26to make themselves healthier. This is something that at
- 37:29different scales, we're all doing right.
- 37:31Many of us are taking some supplements, whether it's just a
- 37:33multivitamin or fish oil or more exploratory things.
- 37:37Beyond that, we change our diets, right people go keto
- 37:40people, do paleo people. Get breakfast right?
- 37:44So, like that kind of playing around with diet and exercise
- 37:50and supplements is something that so many people are doing
- 37:54day-to-day by themselves. And this is just sort of like a,
- 37:57you know, twenty 20s. Internet like look at the far
- 38:01extreme and trying to spotlight on that version of what people
- 38:04have been doing forever. But as far as scientific value
- 38:07like what this could give to the community of like understanding
- 38:10something, there is 0 value in any of the stuff that he is
- 38:14doing. Like anyone who has thought
- 38:16about like how we move from theory to truth in medicine
- 38:22knows that you have to change one variable at a time.
- 38:25You have to do it in a large number of people and.
- 38:29Then you can Start learning little things and it would takes
- 38:33years to learn little things. So saying like, hey, I'm gonna
- 38:37change this and that and I'm gonna combine 20 different
- 38:40things into my protocol and like what's gonna come out of it is
- 38:43like I feel a little better. I feel a little worse for one
- 38:46person. There's no scientific value in
- 38:48that. There's only media value in it.
- 38:50Yeah, this is such a meme with Silicon Valley tech people, I
- 38:54cannot tell you the amount of tech what for to talk out is.
- 38:57Massive combo studies. So like, Wow Pharma is so dumb.
- 39:01They only use one drug at a time, but aging is complex and
- 39:05they should use multiple drugs at a time.
- 39:07And we're going to do these combo studies and I'm like 1.
- 39:10Like the path of getting that approved is like, good fucking
- 39:12luck. But two, you can't actually
- 39:15attribute and tell like aging is such a complex thing.
- 39:17We haven't even gotten one thing through.
- 39:20You're not going to be able to then like, start.
- 39:23Like all the all the other way and have like multiple things
- 39:25that you're permitting over a long period of time.
- 39:28Like these studies take even for us and dogs, we're running a
- 39:30pivotal lifespan extension study.
- 39:32It's going to be at least four to five years and that's in
- 39:35dogs. Like in people it's going to be
- 39:37way longer. So like usually with somebody
- 39:39saying, oh, pharma is so dumb, why didn't they just realize
- 39:42XYZ? The answer is they have realized
- 39:45and there's probably a reason they're not doing it.
- 39:46And there's a lot of other things wrong with pharma to be
- 39:48clear that like, you know, me and James are like, you know,
- 39:51working on countering. But they're not done.
- 39:54That was exactly my question. I mean, yeah, it seems like a
- 39:57premise of some of the longevity spaces, that there's something
- 40:00wrong with Pharmaceutical industry, sort of traditional
- 40:05medical investing, drug development.
- 40:07Like. Another way of asking that is
- 40:09why should venture capitalists who aren't experts in this be
- 40:12the ones asked to fund something?
- 40:14It sort of suggests that there's something broken about the
- 40:17traditional model, or that this is fundamentally different in
- 40:20approach. I see that on you know some of
- 40:23the moon shot ones you guys are talking about, but if you're
- 40:25positioning yourself as more as we believe in standard clinical
- 40:28trials, we want to be you know incrementalist to the extent
- 40:31that's that's possible. Yeah.
- 40:33So I I would say this is probably the stake around which
- 40:37I've built my whole career and something that I've brought to
- 40:42what attribution I can claim for it myself versus all of the
- 40:45other people who have been. Kind of touting a similar idea.
- 40:49But the fund that I built before Cambrian and now Cambrian as one
- 40:54of the larger sort of drug developers in this space was
- 40:57premised around the idea that it's not that the FDA is broken,
- 41:01it's not that pharma is dumb and ignoring this, It is in fact
- 41:04that we are at the precipice of a brand new revolution in
- 41:09science that is just now ready and mature enough for drug
- 41:12development. And it is this.
- 41:14Fertile ground of new science that is going to make the great
- 41:18drugs of the next 10 or 20 years.
- 41:21In the same way that, like, you know, 20 years ago you'd want to
- 41:24be studying basic mechanisms in cancer, which made the best
- 41:28drugs of the 20 Tens and the and the 2000s.
- 41:33And like 15 years ago, you might have been wanting to study basic
- 41:36mechanisms of metabolism and obesity, which led to like the
- 41:39GLIP ones and these sorts of things now.
- 41:42This is not different than the rest of pharma innovation, and
- 41:45it's going to create drugs that are going to be the most
- 41:48important drugs of the next 10 or 20 years.
- 41:50That's the investor pitch and the pitch to pharma and to the
- 41:55FDA that is both most rooted in what the actual scientific
- 41:59reality is and gives the most upside for people spending their
- 42:04time and money making this space happen.
- 42:07So I think that's like the stake.
- 42:09I, I always called it the stepping stone approach to kind
- 42:13of bringing these aging drugs to their best and highest use,
- 42:16which is try to find whichever way makes sense to make those
- 42:19discoveries coming from the basic biology of aging, show
- 42:23that they're safe, effective and ultimately profitable right as
- 42:27quickly as possible. And then you can start doing
- 42:31what me and Celine are most excited about, which is what
- 42:34happens when you start giving this sort of tool.
- 42:37Into the hands of someone where they can use it for prevention
- 42:40before they get sick. And that's not an easy thing to
- 42:42do first, because you need to know in humans that something is
- 42:45really safe and really effective before you can start doing that,
- 42:49generally speaking. Yeah, one thing I will say here
- 42:52that was that I think loyal is a really good example.
- 42:55So I agree with everything in jail said.
- 42:57Like one of the things we've done is like, we try to be like
- 43:00the hill we die on, the hill that we're radical on as a drug
- 43:02approved for lifespan and healthspan, extension and
- 43:04everything else, we are extremely.
- 43:07Traditionally competent on right.
- 43:10It's like I'm you know the the young techie founder, da, da,
- 43:15da, whatever of the company. But like my executive team are
- 43:17experienced pharma executives right?
- 43:20Like they're the best possible people for a job.
- 43:22One thing I will give tech a lot of credit for is loyal never
- 43:24would have been funded by traditional biotech investors of
- 43:27biotech funders, right. I was 24 years old when I
- 43:30started the company. It was basically my first job,
- 43:32like I worked for Laura, but it was a two person fund.
- 43:36We were working on dogs, we were working on lifespan extension
- 43:39and we didn't have anything right.
- 43:41It was an idea and an insight, and this side ended up being
- 43:44correct but nothing else. Who took the first bet?
- 43:47Laura and Greg Rosen, Greg's A Box Group and Laura's at
- 43:51Longevity Fund and then First Round and Collaborative Fund.
- 43:54We're also big investors in the seed round and I mean we'll see,
- 43:57but so far so good but. This is definitely something
- 44:01that, like, I don't think I could have walked into the
- 44:03traditional East Coast biotechs. They would have laughed me out
- 44:05of the room. They would have said, like,
- 44:06apply for our associate program. Like, we'll consider you maybe
- 44:10actually, just kidding, you didn't even like finish your
- 44:12PhD, go home. And so I think there's a line
- 44:15where I take that very seriously that I've brought.
- 44:19Like most of my investors, I'm one of the first times they've
- 44:22invested in a biotech or company like this.
- 44:25I have got responsibility. Super.
- 44:26Seriously. Because I want them to invest in
- 44:28more companies after us and more weird companies.
- 44:31But again, it's like I don't take advantage of that situation
- 44:34by being radical and like doing shit that like reduces
- 44:37probability of success. Like we still are very
- 44:39conservative and everything else except for the radical core
- 44:42ideas of you know a young solo founder woman can build a dog
- 44:46longevity company and a consumer brand around these
- 44:48pharmaceutical products and like hopefully get it approved for
- 44:50lifespan extension. So it's a balance, right?
- 44:53But I think like a lot of these snake oil people really take
- 44:56advantage of the fact that the average Silicon Valley person
- 44:59doesn't understand science or how a drug is approved at all.
- 45:02Yeah, you know, there's this sort of meme that Silicon
- 45:05Valley, you know, hasn't been friendly enough to women.
- 45:08I mean, certainly there aren't sort of as many women founders
- 45:11as you would like. But it's interesting that you're
- 45:13saying in some ways that you found VC sort of more open to
- 45:18the idea of sort of young founder type at least then and
- 45:22you think would. Have been totally.
- 45:24I mean, there's a ton of sexism in Nessa.
- 45:27Like, don't get me wrong. Like the way I would explain it
- 45:30is like when I walk into a room, the assumption of my competency
- 45:33is not zero or positive. Like it might be of a much
- 45:36traditional like bro founder. It's usually negative and then I
- 45:39have to work within that conversation to get them to zero
- 45:42and positive. We're just frustrating because
- 45:43I'm like, I have a lot to learn, etc.
- 45:47But I am a really good operator. Like, we've gotten this company
- 45:49really far in four years with a lot less money than a lot of the
- 45:52other groups have had. And again, starting from zero.
- 45:55But I've kind of gotten like, I used to just get so pissed.
- 45:58Like, I remember I pitched one fund and afterwards I called the
- 46:00partner. I was like, do you not realize
- 46:02your stupid GP was mansplaining longevity to me the entire time?
- 46:05Like, I got so, so irritated, and now I'm just like, whatever,
- 46:10it's fine. I'm gonna be richer anyhow than
- 46:12these guys. And like, I'll create my own
- 46:14fund and support. People building interesting
- 46:18stuff, but you just gotta play the game to win the game.
- 46:20And the game has the rules it has.
- 46:21So I've just been wondering, this whole time, is loyal only
- 46:25about dogs, or is this like a road map to humans?
- 46:28I'm sure there's a world where it's like you get the perfect
- 46:30drug, you're ready to go. But like, how do you think about
- 46:33it in terms of your focus? So it's both loyal has I believe
- 46:39a relatively like. Hard but straightforward path to
- 46:43a multi billion dollar company just off the dog aging drugs.
- 46:46Just if you look at comparable market size dog drugs like
- 46:49heartworm, preventative heart guard makes half a billion a
- 46:52year flea and tick next guard made $1.2 billion last year of
- 46:56revenue, high margin revenue. So there's a clear path there
- 46:59and if we only do that that's really awesome.
- 47:02But dogs are also the best or one of the best biological
- 47:06models of human aging because it Co evolved with us a shared
- 47:08environment for 10s of thousands of years.
- 47:11And most importantly to develop age-related diseases over time.
- 47:15So a dog gets cancer not due to you know it should ton of
- 47:18inbreeding like a mouse has but just environmental factors.
- 47:21A dog gets never thought to get nerve disorders.
- 47:24Dog gets dementia that we've looked at cognitive decline in
- 47:27dogs. My favorite study we ever ran
- 47:30was a cognitive decline study in dogs.
- 47:32They get osteoarthritis. And so if something works in
- 47:35reducing the onset of cognitive decline or cancer or whatever in
- 47:39a dog, which will learn in this thousand dog companion dog study
- 47:43we're running later this year, starting later this year, it's
- 47:46not 1 to 1 to work at a human, but it's as sure as hell really
- 47:49awesome biological insight that might translate over.
- 47:53So yeah, I mean my goal is to build an aging pharmaceutical
- 47:56company. I think agings need larger than
- 47:58oncology. There's no one oncology company.
- 48:00There's no one Parkinson's company.
- 48:02There's gonna be many, but I wanna build one of the defining
- 48:05ones. And hopefully James does too,
- 48:08and we'll be able to talk about the good old days.
- 48:10James, you can go after a bunch of drugs at once, I guess, so
- 48:13you sort of get to hedge your bets.
- 48:14Yeah, I think I know where you're going, which is something
- 48:17along the lines of like we get asked a fair amount, What does
- 48:22like are all of these people who are trying to do real drug
- 48:25development within this? Broad aging biology.
- 48:28Space. Aren't they all competing with
- 48:30each other? Isn't everyone like trying to
- 48:32get the first drug to increase health span and that will be
- 48:36like the pot of gold at the end of the rainbow that one person
- 48:39wins? And it's really fascinating
- 48:41because this ecosystem, this kind of community is uniquely
- 48:49collaborative within any tech or biotech or pharma.
- 48:54Kind of competitive landscape that I've ever seen because so
- 48:59many of the drugs are targeting completely different things,
- 49:03right. So like you have Ozempic and and
- 49:05like Novo Nordisk has their GL P1, right.
- 49:08And then Lily has their GL P1 and it's you're going to take
- 49:11one or the other, right. And and like they both wanted to
- 49:14go and they're like Headtohead competing with each other.
- 49:17Celine's drug and all of our drugs, they don't even target
- 49:19the same molecular pathways. They're just kind of coming from
- 49:23the same broad field of how we studied cellular biology.
- 49:27So Cameron has 15 different drugs and development and none
- 49:30of them are targeting the same two things.
- 49:33This is something so much broader than just like, oh, we
- 49:37found a new way to treat obesity like and it's this pathway which
- 49:41is how you get real head to head competition.
- 49:43This is instead like we've just opened the doors to hundreds of
- 49:48new ways of approaching cellular dysfunction, at its core, of
- 49:52which some will be right and some will be wrong.
- 49:55And they're even going to be approved for different things
- 49:58first and then once they're approved, when you get the first
- 50:01one. That is approved for a healthy
- 50:03lifespan extension, then that will be a tide that raises all
- 50:06ships. Cuz now there are footprints to
- 50:09follow towards a prevention study in the way that the most
- 50:12successful Staten was like the third Staten that was approved,
- 50:16not the first one I. Was just gonna add quickly on
- 50:19here. So loyal is kind of like mini
- 50:22came written in that way. So we have three programs that
- 50:24we're developing concurrently. And the way I thought about it
- 50:28and this is actually like a pretty big fight we had in the
- 50:30early days on the board because like the traditional tech
- 50:33company only develops one product, right, And you focus
- 50:36all your energy on that one product.
- 50:37But the big difference between tech and biotech is that your
- 50:40product is locked in, right? And once you start doing your
- 50:44studies, that is your final product.
- 50:45And you might do like different formulations that are the right,
- 50:47but the active ingredient that's driving the lifespan extension
- 50:50is locked in. And so there is nothing you can
- 50:53do. There's no iteration.
- 50:54There's a product market fit finding you can do to make a
- 50:57drug work if it doesn't work. I always say there's a God in
- 51:00biology, even if you're not religious, because it is
- 51:02predetermined whether our drug will work or not.
- 51:05It's about us finding the truth as effectively as possible.
- 51:08And there's other execution bits we can do to increase
- 51:10probability of success post that binary truth, but that's core
- 51:14importance. So what we did is we have three
- 51:17programs, two around large dog lifespan extension, 1 around old
- 51:20dog lifespan extension that share a really concrete core.
- 51:24That is how do we prove the FDA of the drug works?
- 51:27What does the pivotal lifespan extension study look like?
- 51:30There's a regulatory strategy, but like all these different
- 51:32things and it's an idea that a drug could be developed to
- 51:35extend lifespan extension. And then it's slightly different
- 51:38mechanisms or active ingredients on that.
- 51:41So almost everything is shared that is able to be held true and
- 51:45then we're able to externalize out the risk that we can't
- 51:48control, which is the binary, yes, no, whether the drug works,
- 51:51we're now beyond that like we we have positive data for our drug
- 51:55programs, which is great. But that's how I designed the
- 51:57company early on because I was also very cognizant of the fact
- 52:01that if our first drug failed. It would just blow out in
- 52:04general the opportunity of me or anybody else to build a dog
- 52:07longevity company, even though our first drug failing would
- 52:10have not been at all reflective of the validity of the thesis,
- 52:13right? There's an expected amount.
- 52:15Not every drug works, even if you're operating perfectly.
- 52:20This is the hardest part of pharma that only statistically
- 52:23only about 12% of drugs that start clinical trials get
- 52:28approved and. Within biotech companies, it's
- 52:31slightly better. They do better than pharma or we
- 52:33do better than pharma. It's but still like nearly 20%
- 52:37and that's the highest that you get from the statistical
- 52:40operators. The Brian Johnson idea, I think,
- 52:42you know, people are so excited about it, partially you know,
- 52:45because people want to know what to do with their own health.
- 52:48I mean it's like you know like you sort of said we've had
- 52:51Atkins, we've had so you know intermittent fasting.
- 52:53You know there's so many, so many things.
- 52:56And certainly I obviously like what what you should do in a
- 52:59societal level to prove a drug versus what an individual who is
- 53:03actually aging right now and not cannot wait for for things you
- 53:07know for drugs to get approved. Those are sort of very different
- 53:11considerations and you know you you both are sort of measured in
- 53:16science based. So probably the the last people
- 53:18to sort of like push on everybody what what you think
- 53:22they should do. But I am curious what you would
- 53:24recommend for people now that's sort of available to them or
- 53:28like are yeah, are you taking anything sort of strange
- 53:32yourself? Like, I'm curious in terms of
- 53:34just like an individual like who've looked at this space, how
- 53:37you approach and what you recommend to your family and
- 53:40friends? So I think one of the best
- 53:43predictors slash like rough categorizers of whether somebody
- 53:46you have charlatan or not. Is like how much they work on
- 53:49their own personal longevity. Like all of the people who are
- 53:52like super legit in the field, like Laura Deming, the Longevity
- 53:56Fund founder is like a very famous example of this.
- 53:59They often do things that are like negatively selected for a
- 54:03lifespan extension, right? So, like when I was working at
- 54:05Longevity Fund, all we ate at the fund was like chocolate,
- 54:08Cheerios and dandelion chocolate, and I was like the
- 54:11meals we had at the fund. You know, having pumping up your
- 54:16blood glucose levels that high, not good for longevity.
- 54:19I don't do anything like I work out I guess, but hey, I'm like
- 54:24not doing longevity drugs for myself and I think that's
- 54:26actually a really important thing to like keep cognitively.
- 54:29Like. I think people who intertwine
- 54:31their fear of mortality into their pursuit of aging drugs
- 54:35become dumb, right? Because it's a fear based way of
- 54:38approaching the field. Versus a logical way, they're
- 54:41like, God, I have to find something because it's my
- 54:42mortality on the line. Versus I see this as like my
- 54:48thing to help other people. And like, I try to think about
- 54:50it as other people and try not to focus on myself.
- 54:53Maybe that'll get harder as I get older, I don't know.
- 54:55But I think it's a pretty good predictor.
- 54:57You don't take vitamins or anything.
- 55:00I think literally nothing. Like I'm trying to eat more
- 55:02vegetables. I'm vegetarian, but like, I love
- 55:05on frozen and canned vegetables, OK, like I am.
- 55:09Don't do anything. I do.
- 55:11Just maybe if the drug is approved and your vet says so
- 55:14prescribed her drug, I don't steal it.
- 55:18But no, otherwise not. I don't do anything, James.
- 55:20What's your approach? So I'm like a decade older than
- 55:22Selena's and and I still get called like the young kid on the
- 55:28on the biotech block most of the time.
- 55:30And I take a little bit more of an experimental approach like we
- 55:33were talking about before. I think almost everybody that I
- 55:37know is thinking about. Especially like, so for example,
- 55:40in my my family, we've had two people die of Alzheimer's in the
- 55:46last, you know, in the last five years.
- 55:49My boyfriend's mom is starting to show signs of this.
- 55:53And so we're thinking, okay, well, what can we do to maximize
- 55:56the time that we have healthy to be around and to be with each
- 56:02other. And so there are things that I'm
- 56:04doing, I think. The best, like validated things
- 56:07that we really know will work is don't get diabetes regularly
- 56:13exercise, eat fruits and vegetables.
- 56:16Get enough sleep, don't change time zones every week or two.
- 56:21This is 1. This is one that, like I was I
- 56:24was in Europe last week, I'm in Europe next week.
- 56:26Like it fucks with you for, like, a while.
- 56:31I get sick every time I come back from a big time zone
- 56:33change. Every single time without fail.
- 56:36So, you know, I do play with some supplements, but like,
- 56:40there's some that have real evidence behind them, the best
- 56:42of which is fish oil for the prevention of heart disease.
- 56:45I have two grandparents who died of heart attacks in their 50s.
- 56:49And so, like, I care a lot about my heart health, you know,
- 56:52beyond that, we just don't have a lot of evidence.
- 56:55And so whatever, you know, people are doing, like they can
- 56:58play with this or that, but it's just like it's.
- 57:03Not backed by facts until it is and and the big part of I think
- 57:08this whole field and if if there's one message that I would
- 57:11love someone listening to this to walk away from is like
- 57:14ultimately we need to create new truth in order to know new
- 57:17things. And the only tool in medicine
- 57:20that we have for creating new truth is running randomized
- 57:23placebo-controlled clinical trials which will create one
- 57:27little new piece of knowledge at a time and like that just takes
- 57:30a long ass time. And this is all brand new
- 57:33science where we have a pretty good idea that, like it might
- 57:36work in mice, but before we know that it will work in humans and
- 57:40especially with the diversity of humans that exist, which is way
- 57:43more than the diversity of mice. Like it's just going to be a
- 57:46while before we can think about how this longevity science is
- 57:50going to impact everybody's day-to-day life.
- 57:52There's just not that much outside of the the stuff that we
- 57:56knew before. You know 10 years ago that we've
- 57:59just gotten more and more evidence the placebo effect is
- 58:02so fucking strong that it would outperform almost any drug on
- 58:06the market today. So until you can disentangle
- 58:10what scientifically is going on at their mechanistic level
- 58:14versus what's kind of happening at the psychosomatic or the the
- 58:17placebo level, like we just don't know.
- 58:20So what I advise people is like get excited, do things like try
- 58:25stuff. Right.
- 58:27Be healthy, be active, enjoy life, think that you're going to
- 58:30live a really long time, and then also try to do these basic
- 58:33things that we know are supported by, like the
- 58:36Physiology underlying your body. If you have high cholesterol,
- 58:38take a statin. If you're overweight, like
- 58:42exercise, have a good diet, maybe end up on one of these
- 58:46obesity or metabolic drugs that are pretty good if your doctor
- 58:50recommends but like apart from that.
- 58:53Wait until the science comes out and see if we have like novel M
- 58:57Tor inhibitors or caloric restriction mimetics or AMPK
- 59:00activators that will be coming not that far in the future.
- 59:04If they show to be safe and effective, that could be used
- 59:07for people. But that's really like the next
- 59:10frontier. This is why this whole longevity
- 59:11space it's going to create a world that is so different than
- 59:14the one that we have now, because it will be grounded in
- 59:16truth instead of in speculation. Great.
- 59:22I think that's a great end point for the show.
- 59:23Thank you both for coming out this.
- 59:26Is fun, Celine. I always love doing podcasts
- 59:28with you. Yeah.
- 59:29This was sincerely one of my favorite episodes.
- 59:32I mean, it's such a great topic. So thanks so much.
- 59:37My pleasure. Yeah.
- 59:38Thanks for inviting me. That's our episode.
- 59:40Thanks to James and Celine. Shout out to Tommy Herron, our
- 59:43audio editor, Riley Kinsella, my chief of staff, Young Chomsky
- 59:48for the theme music. Annie Wen for booking the
- 59:50guests, please like comments, subscribe on YouTube and
- 59:54subscribe to the subsetnewcomer.co Thanks so
- 59:57much. Goodbye.
- 59:58Goodbye. Goodbye.
- 1:00:00Goodbye. Goodbye.
- 1:00:01Goodbye. Goodbye, Goodbye, Goodbye.